Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 190

1.

Incidence of Radiologically Isolated Syndrome: A Population-Based Study.

Forslin Y, Granberg T, Jumah AA, Shams S, Aspelin P, Kristoffersen-Wiberg M, Martola J, Fredrikson S.

AJNR Am J Neuroradiol. 2016 Jun;37(6):1017-22. doi: 10.3174/ajnr.A4660. Epub 2016 Feb 4.

PMID:
26846927
2.

Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study.

Granberg T, Uppman M, Hashim F, Cananau C, Nordin LE, Shams S, Berglund J, Forslin Y, Aspelin P, Fredrikson S, Kristoffersen-Wiberg M.

AJNR Am J Neuroradiol. 2016 Jun;37(6):1023-9. doi: 10.3174/ajnr.A4665. Epub 2016 Jan 21.

PMID:
26797137
3.

A single-group pilot feasibility study of cognitive behavioural therapy in people with multiple sclerosis with depressive symptoms.

Chruzander C, Gottberg K, Ytterberg C, Backenroth G, Fredrikson S, Widén Holmqvist L, Johansson S.

Disabil Rehabil. 2016 Jan 10:1-9. [Epub ahead of print]

PMID:
26750510
4.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
5.

MRI-Defined Corpus Callosal Atrophy in Multiple Sclerosis: A Comparison of Volumetric Measurements, Corpus Callosum Area and Index.

Granberg T, Bergendal G, Shams S, Aspelin P, Kristoffersen-Wiberg M, Fredrikson S, Martola J.

J Neuroimaging. 2015 Nov-Dec;25(6):996-1001. doi: 10.1111/jon.12237. Epub 2015 Mar 19.

PMID:
25786805
6.

Is excessive daytime sleepiness a separate manifestation in Parkinson's disease?

Höglund A, Broman JE, Pålhagen S, Fredrikson S, Hagell P.

Acta Neurol Scand. 2015 Aug;132(2):97-104. doi: 10.1111/ane.12378. Epub 2015 Jan 28.

PMID:
25630925
7.

Health-related quality of life in partners of persons with MS: a longitudinal 10-year perspective.

Gottberg K, Chruzander C, Einarsson U, Fredrikson S, Johansson S, Widén Holmqvist L.

BMJ Open. 2014 Dec 16;4(12):e006097. doi: 10.1136/bmjopen-2014-006097.

8.

Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.

Granberg T, Martola J, Bergendal G, Shams S, Damangir S, Aspelin P, Fredrikson S, Kristoffersen-Wiberg M.

Mult Scler. 2015 Aug;21(9):1151-8. doi: 10.1177/1352458514560928. Epub 2014 Dec 5.

PMID:
25480866
9.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19.

PMID:
24554104
10.

Radiologically isolated syndrome: an uncommon finding at a university clinic in a high-prevalence region for multiple sclerosis.

Granberg T, Martola J, Aspelin P, Kristoffersen-Wiberg M, Fredrikson S.

BMJ Open. 2013 Nov 4;3(11):e003531. doi: 10.1136/bmjopen-2013-003531.

11.

A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: changes in disability and the value of different factors in predicting disability and mortality.

Chruzander C, Johansson S, Gottberg K, Einarsson U, Fredrikson S, Holmqvist LW, Ytterberg C.

J Neurol Sci. 2013 Sep 15;332(1-2):121-7. doi: 10.1016/j.jns.2013.07.003. Epub 2013 Jul 26.

12.

Reports of patients and relatives from the CogniCIS study about cognition in clinically isolated syndrome: what are our patients telling us?

Langdon DW, Benedict RH, Wicklein EM, Beckmann K, Fredrikson S.

Eur Neurol. 2013;69(6):346-51. doi: 10.1159/000345698. Epub 2013 Apr 26.

PMID:
23635720
13.

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.

Fredrikson S, McLeod E, Henry N, Pitcher A, Lowin J, Cuche M, Fajutrao L, Perard R, Bates D, Chan A.

J Med Econ. 2013;16(6):756-62. doi: 10.3111/13696998.2013.792824. Epub 2013 Apr 17.

PMID:
23556422
14.

Differences between users and non-users of complementary and alternative medicine among people with multiple sclerosis in Denmark: a comparison of descriptive characteristics.

Skovgaard L, Nicolajsen PH, Pedersen E, Kant M, Fredrikson S, Verhoef M, Meyrowitsch D.

Scand J Public Health. 2013 Jul;41(5):492-9. doi: 10.1177/1403494813481646. Epub 2013 Apr 2.

PMID:
23548494
15.

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Stangel M, Fredrikson S, Meinl E, Petzold A, Stüve O, Tumani H.

Nat Rev Neurol. 2013 May;9(5):267-76. doi: 10.1038/nrneurol.2013.41. Epub 2013 Mar 26. Review.

PMID:
23528543
16.

Use of Complementary and Alternative Medicine among People with Multiple Sclerosis in the Nordic Countries.

Skovgaard L, Nicolajsen PH, Pedersen E, Kant M, Fredrikson S, Verhoef M, Meyrowitsch DW.

Autoimmune Dis. 2012;2012:841085. doi: 10.1155/2012/841085. Epub 2012 Dec 11.

17.

Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.

Bergvall N, Tambour M, Henriksson F, Fredrikson S.

J Med Econ. 2013;16(3):349-57. doi: 10.3111/13696998.2012.755537. Epub 2012 Dec 18.

PMID:
23211038
18.

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O.

Mult Scler. 2013 May;19(6):765-74. doi: 10.1177/1352458512463764. Epub 2012 Nov 1.

19.

[How MS was discovered in Sweden].

Ahremark G, Fredrikson S.

Lakartidningen. 2012 Sep 19-26;109(38):1688-90. Swedish. No abstract available.

PMID:
23094402
20.

Callosal atrophy in multiple sclerosis is related to cognitive speed.

Bergendal G, Martola J, Stawiarz L, Kristoffersen-Wiberg M, Fredrikson S, Almkvist O.

Acta Neurol Scand. 2013 Apr;127(4):281-9. doi: 10.1111/ane.12006. Epub 2012 Sep 18.

PMID:
22988936
Items per page

Supplemental Content

Loading ...
Write to the Help Desk